Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

Korábbi kezelés

• Received treatment with a JAK inhibitor previously .

Más betegség

• History of malignant tumor, excluding the following cases:
  • Malignant tumor that was curatively treated more than 5 years prior to study entry and has not recurred since then;
  • Successful radical resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, preinvasive cervix carcinoma, and other preinvasive cancers.
• Preexisting or history of hepatic encephalopathy, hepatorenal syndrome or liver transplantation.
• Clinically severe gastrointestinal bleeding within 6 months of the start of treatment or any life-threatening bleeding events within 3 months of the start of treatment.

Egyéb

• Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma confirmed by histology or cytology.
• Diffuse tumor lesion.
• Clinically uncontrolled ascites or pleural effusion.

• Age and gender: >18 years old and≤75 years old, both men and women.
• All subjects must have Hepatocellular Carcinoma confirmed by pathological or clinical diagnosis.
• Patients with viable and measurable target lesion per RECIST 1.1.
• Patients with unresectable hepatocellular carcinoma (uHCC) who experienced disease progression after first-line therapy containing immune checkpoint inhibitors.
• Patients who are expected to live more than 3 months.
  • 9.ECOG PS 0-1. 10.Child-Pugh ≤7.